The PIKA COVID-19 Vaccine, developed by Yisheng Biopharma (China), contains a prefusion-stabilized trimerized S protein ectodomain expressed in CHO cells, and the PIKA acts as an adjuvant. Here, PROS1 is linked to COVID-19.